DarioHealth Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 13, 2022, regarding events occurring on June 9, 2022. DarioHealth Corp. (DRIO), a Delaware corporation traded on the Nasdaq Capital Market, entered into a material definitive agreement to secure a new credit facility.
Key Financial Metrics and Debt Structure
The filing details a new senior secured credit facility with OrbiMed Royalty and Credit Opportunities III, LP. The filing does not provide current revenue, profit, or cash flow figures, as this is a transactional report rather than a periodic financial statement.
- Total Facility Size: Up to $50 million.
- Initial Draw: $25 million funded on June 9, 2022.
- Delayed Draw: Up to $25 million available on or before June 30, 2023, subject to revenue requirements.
- Interest Rate: Adjusted SOFR + 9.50% (or 0.50% + 9.50%, whichever is higher).
- Default Interest: Applicable rate + 5.00%.
- Liquidity Covenant: Must maintain at least $10 million in unrestricted cash and cash equivalents.
Material Changes and Equity Considerations
The company incurred a direct financial obligation and issued equity-linked instruments as part of the financing:
- Warrant Issuance: Issued a warrant to purchase 226,586 shares of common stock at an exercise price of $6.62 per share (7-year term).
- Additional Warrant: If the delayed draw is utilized, an additional warrant will be issued for up to 6% of the drawn amount based on a 10-day volume-weighted average price.
- Collateral: Obligations are secured by substantially all assets of the company and its wholly-owned subsidiaries (excluding Dario Health Services Private Limited).
Outlook, Risks, and Covenants
The Credit Agreement includes significant covenants and risks that may impact future operations:
- Revenue Trigger: If net revenue does not meet specified thresholds, the company must repay the outstanding principal in equal monthly installments plus a premium.
- Restrictive Covenants: Limits on incurring additional debt, creating liens, making acquisitions, paying dividends, or engaging in affiliate transactions.
- Events of Default: Include nonpayment, bankruptcy, material adverse effects, and key person events.
- Registration Rights: The company agreed to file a registration statement for the shares underlying the warrants.
Investor Verification Checklist
- Verify the exact amount of fees and expenses deducted from the initial $25 million draw.
- Review the specific revenue thresholds required to access the delayed draw commitment.
- Confirm the impact of the warrant issuance on existing shareholder dilution.
- Assess the company's current unrestricted cash balance against the $10 million covenant requirement.
- Examine the full text of the Credit Agreement (Exhibit 10.1) for detailed default triggers and repayment premiums.